Tagged with R

Biosano “A company active in the Chilean pharmaceutical market has to reinvent its business model every three years because today we are competing against some of the largest multinationals.”     How has the company developed over the past years? Chile has a very open and transparent market, which requires companies to…

mergers The global pharmaceutical sector continues to witness significant mergers and acquisitions activity, with 122 M&A deals completed in 2013. This trend has continued due to several multi-billion dollar deals around the world in 2014, which is already recorded the busiest year for healthcare acquisitions. In Chile, the dealmaking sweeping started in December 2013…

R&D When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain & Portugal explains the new methods implemented in the affiliate, and the importance of the company’s research center in Seville,…

R&D When Jordi Martí came to Celgene in December 2012, one of his main goals was to create a change in the affiliate’s model. The VP Managing Director of Celgene Spain & Portugal explains the new methods implemented in the affiliate, and the importance of the company’s research center in Seville,…

regulatory Eduardo Loyola has been at the helm of Heel’s Chilean affiliate for almost a decade. Prior to his appointment at Heel, Loyola was part of a working group that is responsible for the current regulatory framework for natural products. Loyola elaborates on the innovative marketing strategies Heel has undertaken to…

Spain Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma Spain, discusses the challenges in adapting to the country’s regional peculiarities and the subsidiary’s greater commitment to a much more stakeholder-focused approach. What were…

plasma market In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains one of the most important players in Europe’s highly competitive plasma-derived product market. Luis Cruz, general manager of CSL Behring…

plasma market In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains one of the most important players in Europe’s highly competitive plasma-derived product market. Luis Cruz, general manager of CSL Behring…

generics Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies, and Kern Pharma’s own strategies for growth through in-licensing and local partnerships in Europe and Latin America. What are your…

regulatory PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain & Portugal, he discusses the urgent need for government to trust in and collaborate with the subsidiary in preventative measures for diabetes, as well…

clinical trials Ciro Caravaggio, General Manager at Roche Chile discusses Roche’s mission as a highly specialized biotech with a long presence in Chile. He stresses the importance of the affiliate’s role in clinical trials and the key to success in the Chilean pharmaceutical market. M. Caravaggio, you arrived at the helm of…

R&D Since PharmaBoardroom interviewed Juan López-Belmonte, CEO of Rovi, in 2008, the market has changed drastically. López-Belmonte outlines some of those changes and how Rovi has successfully adapted, having achieved significant growth during a time of economic downturn. Many Spanish companies have disappeared or have been sold in recent years in…